Akebia to refile anemia drug vadadustat after FDA denied appeal
The FDA still won’t approve Akebia’s drug for anemia due to chronic kidney disease, but the agency is apparently keeping the door open to a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
